Prestige Biologics Statistics

Total Valuation

Prestige Biologics has a market cap or net worth of KRW 371.60 billion. The enterprise value is 440.23 billion.

Market Cap	371.60B
Enterprise Value	440.23B

Important Dates

Earnings Date	n/a
Ex-Dividend Date	n/a

Share Statistics

Prestige Biologics has 77.42 million shares outstanding. The number of shares has increased by 19.15% in one year.

Current Share Class	n/a
Shares Outstanding	77.42M
Shares Change (YoY)	+19.15%
Shares Change (QoQ)	+1.97%
Owned by Insiders (%)	20.29%
Owned by Institutions (%)	0.02%
Float	27.34M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	185.35
PB Ratio	2.40
P/TBV Ratio	2.41
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-17.30
EV / Sales	275.70
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-18.57

Financial Position

The company has a current ratio of 0.70, with a Debt / Equity ratio of 0.68.

Current Ratio	0.70
Quick Ratio	0.32
Debt / Equity	0.68
Debt / EBITDA	n/a
Debt / FCF	-4.44
Interest Coverage	-3.04

Financial Efficiency

Return on Equity (ROE)	n/a
Return on Assets (ROA)	n/a
Return on Capital (ROIC)	n/a
Revenue Per Employee	n/a
Profits Per Employee	n/a
Employee Count	n/a
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +11.99% in the last 52 weeks. The beta is 1.10, so Prestige Biologics's price volatility has been higher than the market average.

Beta (5Y)	1.10
52-Week Price Change	+11.99%
50-Day Moving Average	5,171.30
200-Day Moving Average	5,174.70
Relative Strength Index (RSI)	43.19
Average Volume (20 Days)	109,922

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Prestige Biologics had revenue of KRW 1.60 billion and -25.45 billion in losses. Loss per share was -412.69.

Revenue	1.60B
Gross Profit	-14.47B
Operating Income	-34.83B
Pretax Income	-25.45B
Net Income	-25.45B
EBITDA	-22.47B
EBIT	-34.83B
Loss Per Share	-412.69

Full Income Statement

Balance Sheet

The company has 36.56 billion in cash and 105.19 billion in debt, giving a net cash position of -68.63 billion or -886.47 per share.

Cash & Cash Equivalents	36.56B
Total Debt	105.19B
Net Cash	-68.63B
Net Cash Per Share	-886.47
Equity (Book Value)	155.05B
Book Value Per Share	2,002.77
Working Capital	-37.60B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -19.51 billion and capital expenditures -4.20 billion, giving a free cash flow of -23.71 billion.

Operating Cash Flow	-19.51B
Capital Expenditures	-4.20B
Free Cash Flow	-23.71B
FCF Per Share	-306.27

Full Cash Flow Statement

Margins

Gross Margin	n/a
Operating Margin	-2,181.40%
Pretax Margin	-1,593.60%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Prestige Biologics does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-19.15%
Shareholder Yield	-19.15%
Earnings Yield	-8.60%
FCF Yield	-6.38%

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Prestige Biologics has an Altman Z-Score of -0.45. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-0.45
Piotroski F-Score	n/a